BAM
XENE icon

Belpointe Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Belpointe Asset Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-70
Closed -$2.5K – 3408
2023
Q1 		$2.5K Hold
70
– – ﹤0.01% 3246
2022
Q4 		$2.76K Buy
+70
New +$2.55K ﹤0.01% 3153

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Belpointe Asset Management's XENE Position: Q2 2023 in Review

Belpointe Asset Management sold out of Xenon Pharmaceuticals (XENE) in Q2 2023, closing a stake of 70 shares — an estimated $2.5K sold.

Belpointe Asset Management first reported a position in XENE in Q4 2022 and held it in 2 quarters. The position peaked at $2.76K in Q4 2022. 175 funds tracked by Wall St. Rank hold XENE as of Q2 2023.

  • Belpointe Asset Management reported no remaining Xenon Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 70 Xenon Pharmaceuticals shares in Q2 2023, an estimated $2.5K.
  • Belpointe Asset Management first reported a position in Xenon Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Xenon Pharmaceuticals position peaked at $2.76K in Q4 2022.
  • 175 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.